Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM) NIDA (R03) | Apply Online

Opportunity Summary:

The Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM) from the National Institute on Drug Abuse (NIDA) is a discretionary NIH grant opportunity designed to help newly independent investigators launch research careers at the intersection of basic chemistry and drug abuse/addiction science. The central goal is to lower the barrier for early-stage investigators to enter NIDA-relevant chemistry research by supporting exploratory or pilot projects that can generate initial data, prove feasibility, or test novel ideas that may later grow into larger, sustained research programs. In practice, this opportunity is meant for scientists who are early in their independent faculty or equivalent research positions and who want to apply chemical concepts, tools, and methodologies to questions aligned with NIDA's mission.

This funding opportunity uses the NIH Small Research Grant (R03) mechanism. The R03 mechanism is specifically oriented toward smaller, focused projects that can be completed with limited resources and within a compact scope. It commonly supports pilot and feasibility studies, small self-contained research projects, secondary analyses of existing data, development of research methods, and early-stage development of new research technologies. In the context of ECHEM, that means applicants are generally expected to propose well-defined chemistry-centered work that can quickly produce informative results, such as validating an approach, establishing an assay, testing a synthetic strategy, creating or improving an analytical method, or demonstrating a proof-of-concept relevant to substances of abuse, addiction processes, or related biomedical questions NIDA prioritizes.

The announcement is identified as PAS-07-327, indicating a Program Announcement with Set-Aside funds, meaning NIDA reserved funds for applications submitted under this specific announcement. The estimated total funding level listed is $1,500,000. The program sits within the broader federal assistance category CFDA 93.279 (Drug Abuse and Addiction Research Programs). There is no cost sharing or matching requirement, which is typical for NIH research grants and reduces financial burden on applicant organizations.

Eligibility is broad across many organization types, reflecting NIH's wide applicant base. Eligible applicants include public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status, other than universities), for-profit organizations other than small businesses, small businesses, state and local governments (including counties, cities or townships), special district governments, independent school districts, public/Indian housing authorities, and tribal governments and tribal organizations (including federally recognized tribes and other Native American tribal organizations). The eligibility notes also specify that foreign institutions are not eligible to apply, while eligible federal government agencies may apply. Faith-based and community-based organizations are also allowed to apply as long as they meet the applicable eligibility requirements.

Administratively, the opportunity was posted on February 1, 2007, and it used multiple receipt dates rather than a single deadline, directing applicants to consult the full announcement for the specific submission cycles. The archived date is February 2, 2010, meaning the particular announcement is no longer active in its original form, though similar programs or reissued announcements may exist in other years. The sponsoring agency is the National Institutes of Health (NIH), with NIDA as the institute leading the program.

Applicants are directed to the full funding announcement for complete details, including application requirements, review criteria, and submission dates: http://grants.nih.gov/grants/guide/pa-files/PAS-07-327.html. For technical issues accessing the announcement or linking problems, the contact provided is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.

Browse more business programs for Drug Abuse Research and Prevention

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Drug Abuse, Risky Decision Making and HIV/AIDS (R03)

Previous opportunity: Stress Management Interventions to Reduce Risk of Coronary Artery Disease (R01)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAS 07 327

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAS 07 327) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAS 07 327", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.